Thursday, July 17, 2025 7/17/2025

IND Enabling Studies for Small Molecule Anthrax Lethal Factor Inhibitors

Award Number: R01AI104586
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2013
PERIOD OF PERFORMANCE END DATE: 03/31/2018

Group Awards By:

View Award Description

IND Enabling Studies for Small Molecule Anthrax Lethal Factor Inhibitors - DESCRIPTION (provided by applicant): PanThera's goal for the proposed research is to identify a clinical candidate that demonstrates in vivo efficacy in animal models of post-exposure inhalation anthrax and has a safety profile suitable for use in humans as an antidote to anthrax lethal factor intoxication. The 2001 anthrax spore attack via the U.S. mail caused 11 confirmed cases of inhalation anthrax. Despite the administration of frontline antibiotics and modern day intensive care support, only six of these patients survived. This high mortality rate, along with the widespread panic and considerable cleanup cost, starkly defined the seriousness of this bioterrorist event and the extreme threat anthrax poses to national security. Therapeutics currently available to treat anthrax, such as antibiotics and immunotherapeutic agents (vaccines and monoclonal antibodies), show complete protection in animal models when administered pre-exposure. However, their protective capability diminishes dramatically as post-exposure treatment delay times increase, suggesting that toxemia remains a threat to host survival. The complex pathogenesis of anthrax disease includes both bacterial and toxin components, although antibiotics can clear the system of bacteria and shut off the source of the toxins, and biological agents can block the transport of toxins into the cells, no therapeutic is currently available to disarm the toxins already present in the cells. PanThera has identified novel anthrax lethal factor inhibitors (LFIs) with picomolar potency and demonstrated in vivo efficacy in rat, mouse, and rabbit models of anthrax. These LFIs are designed to mitigate both early and late-stage toxemia by acting intracellularly and extracellularly, in contrast to biologics which ac only extracellularly. Small molecule LFIs should also provide a countermeasure against antibiotic resistant strains of B. anthracis (Enhanced Agents) and against novel viral vectors engineered to deliver intracellular anthrax LF toxin (Advanced Agents). The specific aims of the proposed project are: 1) complete lead optimization studies and select a preclinical candidate; 2) conduct early IND-enabling studies sufficient for a pre-IND meeting with the FDA; and 3) complete the remaining IND studies needed for submission of an IND to the FDA. To achieve these aims we have assembled a team of scientists who are leaders in the field of bacterial toxins and anthrax disease. This team of expert collaborators provides us with unique animal models: rat toxin and mouse spore challenge models of anthrax (Leppla lab; NIH), as well as a rabbit inhalation spore challenge model of anthrax infection (Peterson lab; UTMB).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2017 ( Subtotal = $1,600,303 )
2017	2017	HAWAII BIOTECH, INC.	650 IWILEI RD STE 204	HONOLULU	HI	96817	HONOLULU	USA	Allergy and Infectious Diseases Research	000	6	4/20/2017	NON-COMPETING CONTINUATION	$1,600,303
														Subtotal = $1,600,303

Issue Date FY: 2016 ( Subtotal = $1,569,436 )
2016	2016	HAWAII BIOTECHNOLOGY GROUP, INC	99-193 AIEA HEIGHTS DRIVE	AIEA	HI	96701	HONOLULU	USA	Allergy and Infectious Diseases Research	000	5	4/1/2016	NON-COMPETING CONTINUATION	$1,569,436
														Subtotal = $1,569,436

Issue Date FY: 2015 ( Subtotal = $1,593,546 )
2015	2015	HAWAII BIOTECHNOLOGY GROUP, INC	99-193 AIEA HEIGHTS DRIVE	AIEA	HI	96701	HONOLULU	USA	Allergy and Infectious Diseases Research	000	4	3/27/2015	NON-COMPETING CONTINUATION	$1,593,546
														Subtotal = $1,593,546

Issue Date FY: 2014 ( Subtotal = $1,528,431 )
2014	2014	HAWAII BIOTECHNOLOGY GROUP, INC	99-193 AIEA HEIGHTS DRIVE	AIEA	HI	96701	HONOLULU	USA	Allergy and Infectious Diseases Research	002	3	3/24/2014	NON-COMPETING CONTINUATION	$1,528,431
2014	2013	HAWAII BIOTECHNOLOGY GROUP, INC	99-193 AIEA HEIGHTS DRIVE	AIEA	HI	96701	HONOLULU	USA	Allergy and Infectious Diseases Research	000	2	1/8/2014	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$1,126,264
2014	2013	PANTHERA BIOPHARMA LLC	99-193 AIEA HEIGHTS DRIVE	AIEA	HI	96701	HONOLULU	USA	Allergy and Infectious Diseases Research	001	1	1/8/2014	NEW	-$1,126,264
														Subtotal = $1,528,431

Issue Date FY: 2013 ( Subtotal = $1,760,729 )
2013	2013	PANTHERA BIOPHARMA LLC	99-193 AIEA HEIGHTS DRIVE	AIEA	HI	96701	HONOLULU	USA	Allergy and Infectious Diseases Research	000	1	3/27/2013	NEW	$1,760,729
2013	2013	HAWAII BIOTECHNOLOGY GROUP, INC	99-193 AIEA HEIGHTS DRIVE	AIEA	HI	96701	HONOLULU	USA	Allergy and Infectious Diseases Research	002	2	1/8/2014	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$1,126,264
2013	2013	PANTHERA BIOPHARMA LLC	99-193 AIEA HEIGHTS DRIVE	AIEA	HI	96701	HONOLULU	USA	Allergy and Infectious Diseases Research	001	1	1/8/2014	NEW	-$1,126,264
														Subtotal = $1,760,729

Grand Total All Awards = $8,052,445

Top

All Categories

About

Search

Reports

Data Submission

Award Information

IND Enabling Studies for Small Molecule Anthrax Lethal Factor Inhibitors

Award Number: R01AI104586

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2013

PERIOD OF PERFORMANCE END DATE: 03/31/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer